Several other equities research analysts have also issued reports on GTHX. Cowen reiterated a buy rating on shares of G1 Therapeutics in a report on Wednesday, November 8th. BidaskClub upgraded G1 Therapeutics from a sell rating to a hold rating in a report on Wednesday, January 3rd. JPMorgan Chase & Co. lifted their price target on G1 Therapeutics to $30.00 in a report on Monday, February 5th. Finally, Zacks Investment Research lowered G1 Therapeutics from a hold rating to a sell rating in a report on Thursday, February 8th. Two analysts have rated the stock with a sell rating and five have issued a buy rating to the company’s stock. G1 Therapeutics currently has a consensus rating of Hold and a consensus price target of $32.80.
Shares of G1 Therapeutics (NASDAQ GTHX) opened at $24.11 on Thursday. G1 Therapeutics has a 1-year low of $12.04 and a 1-year high of $28.67.
G1 Therapeutics (NASDAQ:GTHX) last announced its quarterly earnings results on Wednesday, February 21st. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by ($0.02). research analysts forecast that G1 Therapeutics will post -2.48 EPS for the current year.
In related news, major shareholder Medimmune Ventures, Inc. sold 200,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $19.75, for a total value of $3,950,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Mark A. Velleca sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $20.01, for a total value of $150,075.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 350,458 shares of company stock valued at $6,939,148.
Several hedge funds have recently modified their holdings of the stock. Teachers Advisors LLC raised its stake in shares of G1 Therapeutics by 44.6% in the 4th quarter. Teachers Advisors LLC now owns 13,818 shares of the company’s stock valued at $274,000 after acquiring an additional 4,260 shares in the last quarter. Two Sigma Investments LP bought a new position in shares of G1 Therapeutics in the 4th quarter valued at approximately $493,000. Ellington Management Group LLC bought a new position in shares of G1 Therapeutics in the 4th quarter valued at approximately $294,000. Goldman Sachs Group Inc. raised its stake in shares of G1 Therapeutics by 237.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 28,308 shares of the company’s stock valued at $562,000 after acquiring an additional 19,923 shares in the last quarter. Finally, Deutsche Bank AG raised its stake in shares of G1 Therapeutics by 171.6% in the 4th quarter. Deutsche Bank AG now owns 19,208 shares of the company’s stock valued at $380,000 after acquiring an additional 12,136 shares in the last quarter. 52.01% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “G1 Therapeutics’ (GTHX) Buy Rating Reiterated at BTIG Research” was first published by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://transcriptdaily.com/2018/02/25/g1-therapeutics-gthx-buy-rating-reiterated-at-btig-research.html.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.